1. Technical & Derivative Report 20TH APRIL 2018 www.rudrainvestment.com

2. Daily Trading Bites NIFTY SNAPSHOT INDEX NIFTY 50 BANKNIFTY OPEN 10581 25199 HIGH 10585 25199 LOW 10550 25041 CLOSE 10579 25175 ADVANCE/DECLINE RATIO OPEN INTEREST AND VOLUME INDEX NIFTY INDEX NIFTY OI CURRENT 26850300 PREVIOUS 27148725 % CHANGE 1.01 ADVANCES 30 DECLINES 20 NIFTY VOLUME 75007 117774 1.57 BANKNIFTY OI 1898240 73695 1884840 90744 0.99 1.23 UNCHANGED 0 BANKNIFTY VOLUME www.rudrainvestment.com

3. NIFTY GAINERS NIFTY LOSERS SYMBOL CMP % CHANGE SYMBOL CMP % CHANGE BPCL 376.40 7.11 HINDLACO 264.20 8.81 HINDALCO 301.65 5.62 VEDL 310.65 6.65 IOC 158.20 4.09 TATASTEEL 621.40 3.29 TITAN 952.00 2.57 YESBANK 318.50 2.89 HDFC 1861.00 0.89 BHARTIARTL 394.50 2.64 www.rudrainvestment.com

4. FII ACTIVITIES ( RS. IN CRORE) Market News: •Future Enterprise raises Rs. 300 crore on private placement basis by allotting Non-Convertible Debentures (NCDs). • Lupin receives tentative FDA approval for generic AndroGel®, 1.62% •Future Consumer makes further investment in IFPPL a subsidiary company by acquiring the entire stake held by Capital Foods in IFPPL. company's holding in IFPPL stands increased to 99.93% of the paid-up sharecapital of IFPPL. FII GROSS PURCHASE GROSS SALES NET PURCHASE/ SALES 18-Apr-2018 17-Apr-2018 16-Apr-2018 4064.60 4559.84 3923.95 4980.31 5511.23 4232.08 915.71 951.39 308.13 DII ACTIVITIES ( RS. IN CRORE) DII GROSS PURCHASE GROSS SALES NET PURCHASE/ SALES 18-Apr-2018 3379.06 2509.36 869.70 17-Apr-2018 3232.34 2508.53 723.81 16-Apr-2018 2998.66 3027.63 28.97 www.rudrainvestment.com

5. NIFTY WRAP CHART NIFTY Outlook Nifty settled down 23 points to 10526. The market are trading in a range on Thursday taking clue from their global peers. Stock-specific action will continue to impact sentiment during the day, given that we are in the middle of the March 2018 quarterly result season. The immediate resistance and support are 10630 and 10420 respectively. www.rudrainvestment.com

6. Glenmark receives ANDA approval for generic Protopic Ointment Glenmark Pharmaceuticals Inc., USA(Glenmark) has been granted final approval by the United States Food & DrugAdministration (USFDA) for Tacrolimus Ointment, 0.1%, the generic version of Protopic Ointment, 0.1%, of Leo Pharma AS. According to IQVIA sales data forthe 12 month period ending February 2018, the Protopic Ointment, 0.1% market2achieved annual sales of approximately $109.0 million. www.rudrainvestment.com

7. DISCLAIMER: Trading/investing in Stock Market involves considerable risk; you may lose part or all of the initial investment. It is not ideal for all types of investors. Past performance may not necessarily be repeated in the future. The views & tips provided is based on information & analysis which is believed to be accurate. This information is provided to enable you to make your own investment decisions and should not be construed as investment advice. Rudra Investment not offer any product/service with assured/guaranteed returns. The anticipatory moves mentioned are purely subject to technical studies and does not take into consideration sudden currency volatility and data events. The author, directors and/or employees of Rudra Investment cannot be held responsible for the accuracy of the tips. For more information and terms & condition kindly visit our website. All information offered at Rudra Investment is copyright protected and copying or redistribution of information, reports and news is strictly prohibited. Our visitors do acknowledge that warranty that is offered in connection with services and products described herein is offered completely by the advertiser or supplier of that product and not by Rudra Investment. We do not warrant that access to our site and relevant services would be error free or uninterrupted that defects gets corrected. We are not accountable for viruses, irregularities, damage to the computers that result from availing, accessing or downloading any information from our website. For More Info Visit Here:- http://rudrainvestment.com/